Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Clinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older.

22. mai 2026 oppdatert av: Ab&B Bio-tech Co., Ltd.JS

A Randomized, Blinded, Controlled Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) (Adjuvanted) in Adults Aged 18 Years and Older.

The primary objective of the phase I trial is to evaluate the safety and tolerability of different doses of the recombinant respiratory syncytial virus vaccine (CHO cell) (Adjuvanted) in adults aged 18 years and older, with the secondary objective being to assess its immunogenicity. The primary objectives of the phase II trial are to evaluate the immunogenicity and safety of the recombinant respiratory syncytial virus vaccine (CHO cell) (Adjuvanted) with different adjuvant ratios in adults aged 60 years and older, with the secondary objective being to evaluate the persistence of immune responses.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

470

Fase

  • Fase 2
  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Sichuan
      • Zigong, Sichuan, Kina
        • Rekruttering
        • Zigong Center for Disease Control and Prevention
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ting Huang, Bachelor

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • Males or females aged 18 years and older at the time of enrollment (aged 18 years and older for the phase I part; aged 60 years and older for the phase II part), who are able to provide legal proof of identity.
  • Voluntarily agree to participate in the trial, able to fully understand and sign the informed consent form.
  • Able to attend all scheduled follow-up visits and comply with the requirements of the clinical trial protocol to complete the study.
  • Female participants must meet the following criteria: In the phase I part, women of childbearing potential* must have a negative pregnancy test prior to enrollment and be willing to use effective contraceptive measures for 12 months after receiving the investigational vaccine; in the phase II part, only women of non-childbearing potential will be enrolled.

    • Women of childbearing potential: Defined as females who have experienced menarche and have not yet entered menopause, unless permanently sterile, such as documented bilateral salpingectomy, bilateral oophorectomy, or hysterectomy; menopause is defined as amenorrhea for 12 consecutive months without other medical cause.

[Effective contraceptive measures include: oral contraceptives, injectable contraceptives, subdermal implants or hormonal patches, intrauterine device (IUD), sterilization surgery, abstinence (no sexual intercourse), male condoms, etc.; rhythm method, withdrawal, and emergency contraception are not considered effective contraceptive measures.]

  • Axillary body temperature ≤ 37.0°C measured on site prior to vaccination on the day of vaccination.

Exclusion Criteria:

  • Clinically significant laboratory abnormalities that, in the investigator's comprehensive judgment, preclude enrollment (applicable only to the phase I part).
  • Pregnant or breastfeeding women.
  • A clear diagnosis of RSV infection or a history of RSV infection-related respiratory disease within 6 months prior to vaccination.
  • Use of immunoglobulins or/and any blood products or plasma derivatives within 3 months prior to vaccination, or planned use during the study.
  • Treatment with immunomodulators (including immunosuppressants and immunostimulants) within 6 months prior to vaccination (e.g., long-term use of systemic glucocorticoids for ≥14 days at a dose of ≥2 mg/kg/day or ≥20 mg/day prednisone or equivalent) (excluding inhaled, intra-articular, and topical steroids).
  • Administration or planned use of long-acting immunomodulatory drugs (e.g., infliximab) at any time during the study.
  • A history of severe allergic reactions (e.g., anaphylactic shock, allergic laryngeal edema, Henoch-Schönlein purpura, thrombocytopenic purpura, Arthus reaction) following any previous vaccination or drug use, or a family history of severe allergies.
  • Impaired immune function or a diagnosis of congenital or acquired immunodeficiency, or human immunodeficiency virus (HIV) infection.
  • A personal or family history of convulsions, epilepsy, encephalopathy, psychiatric disorders, or neurological diseases (such as Guillain-Barré syndrome, Miller Fisher syndrome).
  • A diagnosis of lymphoproliferative disease or malignant tumor within 5 years.
  • Clinically significant electrocardiogram (ECG) abnormalities as determined by the investigator (applicable only to the phase I part).
  • Previous vaccination with any licensed or investigational RSV vaccine prior to enrollment, or planned vaccination during the study.
  • Receipt of any vaccine within 14 days prior to vaccination, or any live vaccine within 30 days prior to vaccination.
  • An acute disease or an acute exacerbation of a chronic disease within 3 days prior to vaccination, or use of antipyretic, analgesic, or anti-allergy medications.
  • Suspected or known alcohol abuse or alcohol dependence (referring to a drinking pattern that causes serious mental or physical health problems) or drug abuse.
  • A history of thrombocytopenia or other coagulation disorders that may contraindicate intramuscular injection.
  • Severe or unstable chronic diseases, including but not limited to cardiovascular diseases [e.g., hypertension uncontrolled by medication (on-site blood pressure measurement prior to vaccination: systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg), coronary heart disease, myocarditis, pericarditis, atrial fibrillation], metabolic diseases (e.g., poorly controlled diabetes), hematological disorders (e.g., severe anemia, hemophilia), hepatic or renal diseases, digestive system diseases, respiratory system diseases (e.g., chronic obstructive pulmonary disease, active pulmonary tuberculosis, other severe respiratory diseases).

Note: For participants aged 60 years and older, those with pre-existing stable disease may be enrolled. This is defined as participants who may have underlying conditions such as hypertension or diabetes, provided that symptoms and signs are stable and medically controllable as assessed by the investigator prior to vaccination, and who have not required changes to the treatment/medication regimen or hospitalization due to the underlying condition within 3 months.

  • A history of confirmed immune-mediated/autoimmune diseases (e.g., cold agglutinin hemolytic anemia, lymphadenopathy, eosinophilia, systemic lupus erythematosus, gout, hyperuricemia, acute disseminated encephalomyelitis, immune thrombocytopenia, autoimmune aplastic anemia, autoimmune neutropenia, autoimmune lymphoproliferative syndrome, thrombocytopenic purpura).
  • Asplenia or functional asplenia, as well as any condition resulting in asplenia or splenectomy.
  • Currently participating in or planning to participate in another clinical study involving investigational or unregistered products (drugs, vaccines, medical devices, etc.) during this study.
  • Any other condition that, in the investigator's judgment, makes the individual unsuitable for participation in this clinical trial.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo gruppe
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
Eksperimentell: Investigational Vaccine 1 (Low Dose) Group
The vaccine is administered as a single 0.25 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
Eksperimentell: Investigational Vaccine 2 (Low Dose) Group
The vaccine is administered as a single 0.25 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
Eksperimentell: Investigational Vaccine 1 Group
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
Eksperimentell: Investigational Vaccine 2 Group
The vaccine is administered as a single 0.25 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
Eksperimentell: Investigational Vaccine 3 Group
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.
Placebo komparator: Adjuvant Control Group
The vaccine is administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the upper arm on Day 0.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of solicited (local and systemic) adverse events (AEs) within 14 days post-vaccination.
Tidsramme: Within 14 days post-vaccination.
Within 14 days post-vaccination.
Incidence of unsolicited AEs within 30 days post-vaccination.
Tidsramme: Within 30 days post-vaccination.
Within 30 days post-vaccination.
Incidence of clinically significant laboratory abnormalities(blood biochemistry, blood routine, coagulation function, urinalysis) on Day 3 post-vaccination, and incidence of clinically significant ECG abnormalities on Days 3, 14, and 30 post-vaccination.
Tidsramme: On Days 3, 14, and 30 post-vaccination
Applicable to Phase I only
On Days 3, 14, and 30 post-vaccination
Incidence of serious adverse events (SAEs) and adverse events of special interest (AESIs) within 12 months post-vaccination.
Tidsramme: Within 12 months post-vaccination.
Within 12 months post-vaccination.
At 1 month post-vaccination: geometric mean titer (GMT) of neutralizing antibodies against RSV-A and RSV-B.
Tidsramme: At 1 month post-vaccination
Applicable to Phase Ⅱ only
At 1 month post-vaccination
At 1 month post-vaccination: seroresponse rate (SRR) of neutralizing antibodies against RSV-A and RSV-B.
Tidsramme: At 1 month post-vaccination
Applicable to Phase Ⅱ only
At 1 month post-vaccination
At 1 month post-vaccination: geometric mean fold rise (GMFR) of neutralizing antibodies against RSV-A and RSV-B.
Tidsramme: At 1 month post-vaccination
Applicable to Phase Ⅱ only
At 1 month post-vaccination
At 1 month post-vaccination: geometric mean concentration (GMC) of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Tidsramme: At 1 month post-vaccination
Applicable to Phase Ⅱ only
At 1 month post-vaccination
At 1 month post-vaccination: SRR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Tidsramme: At 1 month post-vaccination
Applicable to Phase Ⅱ only
At 1 month post-vaccination
At 1 month post-vaccination: GMFR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Tidsramme: At 1 month post-vaccination
Applicable to Phase Ⅱ only
At 1 month post-vaccination

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
At 1 month post-vaccination: GMT of neutralizing antibodies against RSV-A and RSV-B.
Tidsramme: At 1 month post-vaccination
Applicable to Phase I only
At 1 month post-vaccination
At 1 month post-vaccination: SRR of neutralizing antibodies against RSV-A and RSV-B.
Tidsramme: At 1 month post-vaccination
Applicable to Phase I only
At 1 month post-vaccination
At 1 month post-vaccination: GMFR of neutralizing antibodies against RSV-A and RSV-B.
Tidsramme: At 1 month post-vaccination
Applicable to Phase I only
At 1 month post-vaccination
At 1 month post-vaccination: GMC of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Tidsramme: At 1 month post-vaccination
Applicable to Phase I only
At 1 month post-vaccination
At 1 month post-vaccination: SRR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Tidsramme: At 1 month post-vaccination
Applicable to Phase I only
At 1 month post-vaccination
At 1 month post-vaccination: GMFR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Tidsramme: At 1 month post-vaccination
Applicable to Phase I only
At 1 month post-vaccination
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMT of neutralizing antibodies against RSV-A and RSV-B.
Tidsramme: At 14 days, 6 months, 12 months, and 24 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 6 months, 12 months, and 24 months post-vaccination
At 14 days, 6 months, 12 months, and 24 months post-vaccination: SRR of neutralizing antibodies against RSV-A and RSV-B.
Tidsramme: At 14 days, 6 months, 12 months, and 24 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 6 months, 12 months, and 24 months post-vaccination
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMFR of neutralizing antibodies against RSV-A and RSV-B.
Tidsramme: At 14 days, 6 months, 12 months, and 24 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 6 months, 12 months, and 24 months post-vaccination
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMC of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Tidsramme: At 14 days, 6 months, 12 months, and 24 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 6 months, 12 months, and 24 months post-vaccination
At 14 days, 6 months, 12 months, and 24 months post-vaccination: SRR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Tidsramme: At 14 days, 6 months, 12 months, and 24 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 6 months, 12 months, and 24 months post-vaccination
At 14 days, 6 months, 12 months, and 24 months post-vaccination: GMFR of pre-F specific IgG antibodies against both RSV-A and RSV-B subtypes.
Tidsramme: At 14 days, 6 months, 12 months, and 24 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 6 months, 12 months, and 24 months post-vaccination
At 14 days, 1 month, and 6 months post-vaccination: counts of CD4+ and CD8+ T cells expressing at least two activation markers (IFN-γ, IL-2, TNF-α, CD40L)
Tidsramme: At 14 days, 1 month, and 6 months post-vaccination
Applicable to Phase Ⅱ only
At 14 days, 1 month, and 6 months post-vaccination

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Ting Huang, Bachelor, Sichuan Center for Disease Control and Prevention

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

14. mai 2026

Primær fullføring (Antatt)

14. september 2027

Studiet fullført (Antatt)

14. august 2029

Datoer for studieregistrering

Først innsendt

29. april 2026

Først innsendt som oppfylte QC-kriteriene

6. mai 2026

Først lagt ut (Faktiske)

13. mai 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

27. mai 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

22. mai 2026

Sist bekreftet

1. mai 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere